Portage Biotech (PRTG) Competitors

Portage Biotech (NASDAQ:PRTG) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

Which has higher valuation and earnings, PRTG or ALXO?

ALX Oncology is trading at a lower price-to-earnings ratio than Portage Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Portage Biotech	N/A	N/A	-$75.34M	-$41.65	-0.15
ALX Oncology	N/A	N/A	-$160.80M	-$2.47	-0.22

Does the media refer more to PRTG or ALXO?

In the previous week, ALX Oncology had 1 more articles in the media than Portage Biotech. MarketBeat recorded 6 mentions for ALX Oncology and 5 mentions for Portage Biotech. Portage Biotech's average media sentiment score of 0.99 beat ALX Oncology's score of 0.84 indicating that Portage Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Portage Biotech	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ALX Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer PRTG or ALXO?

ALX Oncology received 44 more outperform votes than Portage Biotech when rated by MarketBeat users. Likewise, 64.77% of users gave ALX Oncology an outperform vote while only 59.09% of users gave Portage Biotech an outperform vote.

Company	Underperform	Outperform
Portage Biotech	Outperform Votes 13 59.09%	Underperform Votes 9 40.91%
ALX Oncology	Outperform Votes 57 64.77%	Underperform Votes 31 35.23%

Do insiders and institutionals hold more shares of PRTG or ALXO?

13.4% of Portage Biotech shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 42.1% of Portage Biotech shares are owned by insiders. Comparatively, 33.4% of ALX Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Is PRTG or ALXO more profitable?

ALX Oncology's return on equity of -93.02% beat Portage Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Portage Biotech	N/A	-342.34%	-196.47%
ALX Oncology	N/A	-93.02%	-70.67%

Do analysts recommend PRTG or ALXO?

ALX Oncology has a consensus target price of $3.30, suggesting a potential upside of 510.32%. Given ALX Oncology's stronger consensus rating and higher probable upside, analysts plainly believe ALX Oncology is more favorable than Portage Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Portage Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
ALX Oncology	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Which has more risk and volatility, PRTG or ALXO?

Portage Biotech has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Comparatively, ALX Oncology has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500.

Summary

ALX Oncology beats Portage Biotech on 11 of the 15 factors compared between the two stocks.